Resverlogix Corp
Company Profile
Business description
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Contact
4820 Richard Road South West
Suite 300
CalgaryABT3E 6L1
CANT: +1 403 254-9252
E: sarah@resverlogix.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
18
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,379.70 | 42.40 | -0.50% |
CAC 40 | 7,409.11 | 58.74 | 0.80% |
DAX 40 | 19,254.97 | 177.43 | 0.93% |
Dow JONES (US) | 42,052.19 | 288.73 | 0.69% |
FTSE 100 | 8,177.15 | 67.05 | 0.83% |
HKSE | 20,506.43 | 189.10 | 0.93% |
NASDAQ | 18,239.92 | 144.77 | 0.80% |
Nikkei 225 | 38,053.67 | 1,027.58 | -2.63% |
NZX 50 Index | 12,559.28 | 79.62 | -0.63% |
S&P 500 | 5,728.80 | 23.35 | 0.41% |
S&P/ASX 200 | 8,118.80 | 41.20 | -0.50% |
SSE Composite Index | 3,272.01 | 7.81 | -0.24% |